EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination

Kevin D Dieckhaus iD, Min-Jung Kim iD, Jian-Bing Shen, Tina S Liang, Michael J Kleinberg, Kristen M Siedlarz, David B Banach, Mark L Metersky, Rob P Fuller, Eric M Mortensen iD, Bruce T Liang

Vaccines · 04.02.2023 · 11 (2) · 358

DOI: 10.3390/vaccines11020358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 04.02.2023. Verfasst von Kevin D Dieckhaus und 10 weiteren Autor:innen. Beteiligte Einrichtung: UConn Health, Farmington, CT 06030, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Connecticut Health Center, COVID-19 Research Fund from the UConn School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in reducing HCW susceptibility to SARS-CoV-2, however, neutralizing antibody responses subside with time and may be influenced by many variables. We sought to understand the dynamics between vaccine products, prior clinical illness from SARS-CoV-2, and incidence of vaccine-associated adverse reactions on antibody decay over time in HCWs at a university medical center. A cohort of 296 HCWs received standard two-dose vaccination with either bnt162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) and were evaluated after two, six, and nine months. Subjects were grouped by antibody decay curve into steep antibody decliners gentle decliners. Vaccination with mRNA-1273 led to more sustained antibody responses compared to bnt162b2. Subjects experiencing vaccine-associated symptoms were more likely to experience a more prolonged neutralizing antibody response. Subjects with clinical SARS-CoV-2 infection prior to vaccination were more likely to experience vaccination-associated symptoms after first vaccination and were more likely to have a more blunted antibody decay. Understanding factors associated with vaccine efficacy may assist clinicians in determining appropriate vaccine strategies in HCWs.

Schlagwörter

Stichwörter der Autor:innen

COVID-19SARS-CoV-2bnt162b2healthcare workersmRNA-1273neutralizing antibody

Autor:innen und Institutionen

  • UConn Health, Farmington, CT 06030, USA.

ORCID-Profile: Kevin D Dieckhaus, Min-Jung Kim, Eric M Mortensen

Förderung

  • University of Connecticut Health Center
  • COVID-19 Research Fund from the UConn School of Medicine

Zitieren

APA

Dieckhaus, K. D., Kim, M. J., Shen, J. B., Liang, T. S., Kleinberg, M. J., Siedlarz, K. M., Banach, D. B., Metersky, M. L., Fuller, R. P., Mortensen, E. M., & Liang, B. T. (2023). SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination. Vaccines, 11(2), 358. https://doi.org/10.3390/vaccines11020358

Vancouver

Dieckhaus KD, Kim MJ, Shen JB, Liang TS, Kleinberg MJ, Siedlarz KM, et al. SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination. Vaccines. 2023;11(2):358. doi:10.3390/vaccines11020358

BibTeX
@article{Dieckhaus2023,
  author = {Dieckhaus, Kevin D and Kim, Min-Jung and Shen, Jian-Bing and Liang, Tina S and Kleinberg, Michael J and Siedlarz, Kristen M and Banach, David B and Metersky, Mark L and Fuller, Rob P and Mortensen, Eric M and Liang, Bruce T},
  title = {SARS-CoV-2 Antibody Dynamics in Healthcare Workers after mRNA Vaccination},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {2},
  pages = {358},
  doi = {10.3390/vaccines11020358}
}
Kostenlos starten →